Prostate cancer is one of the most commonly diagnosed men's cancers and remains one of
the leading causes of cancer death. The development of approaches to the treatment of this …

Prostate cancer (PC) is the second most commonly occurring cancer in men. Conventional
chemotherapy has wide variety of disadvantages such as high systemic toxicity and low …

Most patients with advanced prostate cancer (PCa) will develop metastatic castration-
resistant prostate cancer (mCRPC) after androgen deprivation therapy, at this time the tumor …

Combination of targeted delivery and controlled release is a powerful technique for cancer
treatment. In this paper, we describe the design, synthesis, structure validation and …

This work describes the enhancement of a novel antitumor therapeutic platform that
combines advantages from small-molecule drug conjugates (SMDCs) and antibody drug …

Prostate cancer is the second most common type of cancer among men. The main method of
its treatment is androgen deprivation therapy, which has a wide range of side effects. One of …

Clinical applications of camptothecin (CPT) have been heavily hindered due to its non-
targeted toxicity, active lactone ring instability, and poor water solubility. Targeted drug …

Prostate cancer is the second most common cancer among men. We designed and
synthesized new ligands targeting prostate-specific membrane antigen and suitable for …

The purpose of this study is to synthesis and evaluate the antitumor efficacy of a novel
carboxymethyl chitosan–docetaxel (CMCS–DTX) conjugates and the availability of CMCS …

Cancer is one of the leading social problems of the modern world. Today prostate cancer is
the second leading cause of cancer deaths among men. Targeted drug delivery is widely …